SAN DIEGO (AP) ¿ Cadence Pharmaceuticals Inc. said Thursday its fourth-quarter loss narrowed slightly on lower research and development expenses.

The company lost $14 million, or 37 cents per share, compared with a loss of $14.2 million, or 50 cents per share, during the same period a year prior. Shares outstanding jumped to 38.2 million in the recent quarter from 28.7 million in the year-ago period. There was no revenue recorded in either quarter.

Analysts polled by Thomson Reuters expected a loss of 36 cents per share.

Operating costs fell to $13.5 million from $14.6 million.

The company also said it cut development of Omigard, which was aimed at treating catheter-related infections. It expects operating expenses to fall in 2009 without that program.

Shares of Cadence Pharmaceuticals gained 20 cents, or 3.3 percent, to close at $6.20.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

If you liked this article you might like

What's Behind the Surge in Energy Stocks

Hillary Clinton Says Prosecuting Individuals is Key to Wall Street Reform